For example, recent evidence pointed to GFAP as an important biomarker for progressive MS [148,149], as increased GFAP levels could help to delineate the transition into the late phase of subclinical cognitive decline, preceding progressive MS. Here, GFAP is linked to myeloid sarcoma.